In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines.

Heart disease is often seen as a problem that only affects older adults, but more and more young people are being diagnosed ...

Cholesterol is a type of fat found in your blood, and while your body needs it to create healthy cells, having high cholesterol levels can increase your risk of heart disease ...

For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical signs and family history to suggest familial hypercholesterolemia (FH ...

Do you have high cholesterol? You're not alone — millions of adults in the United States face this common but serious issue. High cholesterol increases the risk of heart disease, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Eli Lilly & Co. has divulged relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of diabetes, stroke, atherosclerosis, pulmonary hypertension, chronic obstructive ...

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.